Work

Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow® rapid and PARI LC Plus® nebulisers in cystic fibrosis patients

Year: 2012

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Pulmonary Pharmacology & Therapeutics

DOI: 10.1016/j.pupt.2012.12.002

Authors: Mirco Govoni, Gianluigi Poli, Daniela Acerbi, Debora Santoro, Helen Cicirello, Ottavia Annoni, Jozef Ružička

Institutions: Chiesi (Italy), Chiesi (United States), CROSS Research SA (Switzerland)

Language: English

Topic: Cystic Fibrosis Research Advances

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Novartis, Chiesi Farmaceutici

OpenAlex ID: W2048055596

FWCI: 2.205

Cites: 33

Cited by: 22

Related to: 10